bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
5/6/2013 6:43:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Wendy Dixon, Ph.D., and David Schenkein, M.D., have joined the company’s board of directors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by